Consort Diagram



Baseline Characteristics

The following section summarises data collected at the time of screening and registration for all 6 registered patients.

Table 1 and 2 presents summaries of demographics and disease history.

Table 1: Summary of demographics and disease history

	N = 6
Age (Years)	
Median (Q1, Q3)	68 (62, 69)
Mean (SD)	67 (5)
Min, Max	61, 73
Sex	
Male	4 (67%)
Female	2 (33%)
Was the patient enrolled on to the MoTD trial?	
Yes	4 (67%)
No	2 (33%)
Disease diagnosed	
AML	1 (17%)
MDS	1 (17%)
CMML	1 (17%)
CLL	0 (0%)
MM	0 (0%)
Lymphoplasmacytic lymphoma	0 (0%)
CML	0 (0%)
Myelofibrosis	3 (50%)
Is the patient on steroids?	
Yes	6 (100%)
No	0 (0%)
Time from date of underlying disease diagnosis to registration (months)	
Median (Q1, Q3)	12 (10, 21)
Mean (SD)	18 (13)
Min, Max	9, 43
Time from date of acute GvHD diagnosis to registration (Days)	
Median (Q1, Q3)	6 (5, 10)
Mean (SD)	18 (29)
Min, Max	4, 76
Time from date of most recent allogenic stem cell transplant to registration (months)	
Median (Q1, Q3)	4 (2, 5)
Mean (SD)	3 (1)
Min, Max	2, 5

Table 2: Summary of Age (Years)

	N = 6
Age	
< 18	0 (0%)
18-64	2 (33%)
65-84	4 (67%)
85+	0 (0%)

Table 3 summarises the steroid treatment received by participants prior to registration.

Table 3: Summary of Steroid Treatment received prior to registration

	N = 6
Steroid Treatment	
Budesonide oral, Methylprednisolone IV	1 (17%)
Methylprednisolone IV	3 (50%)
Methylprednisolone IV, Prednisolone oral	2 (33%)

Table 4 summarises the time taken from date of diagnosis to date the screening biomarker assay sample was taken.

Table 4: Time from acute GvHD diagnosis to screening biomarker assay sample taken (days)

	N = 6
Time from acute GvHD diagnosis to screening biomarker assay sample taken (days)	
Median (Q1, Q3)	1 (0, 1)
Mean (SD)	13 (29)
Min, Max	0, 72

A physical examination was performed at screening for 5 registered patients. Table 5 summarises the physical examination results at screening. Table 6 summarises the abnormalities specified.

Table 5: Physical Examination Result at Screening

	N = 5
Result	
Abnormal	4 (80%)
Normal	1 (20%)

Table 6: Physical Examination Result at Screening: Abnormality Specified

	N = 4
Abnormality Specified	
Pedal oedema. Abdominal tenderness.	1 (25%)
Severe abdomen pain on palpation and <25% maculopapular rash	1 (25%)
Skin rashes and Redding on face, eyes and ears. Diarrhoea.	1 (25%)
Some distension with hepatosplenomegaly	1 (25%)

Table 7 summarises vital signs at screening for all 6 registered participants.

Table 7: Summary of Vital Signs Collection at Screening

	N = 6
Height (cm)	
Median (Q1, Q3)	175 (163, 180)
Mean (SD)	173 (10)
Min, Max	160, 185
Weight (kg)	
Median (Q1, Q3)	72 (58, 76)
Mean (SD)	70 (14)
Min, Max	54, 91
Body Surface Area (m^2)	
Median (Q1, Q3)	1.90 (1.60, 1.98)
Mean (SD)	1.84 (0.21)
Min, Max	1.56, 2.09
Pulse (bpm)	
Median (Q1, Q3)	80 (62, 86)
Mean (SD)	75 (14)
Min, Max	54, 88
Temperature (degrees C)	
Median (Q1, Q3)	36.45 (36.30, 36.60)
Mean (SD)	36.43 (0.22)
Min, Max	36.10, 36.70
Oxygen Saturation (%)	
Median (Q1, Q3)	98 (96, 98)
Mean (SD)	97 (1)
Min, Max	96, 99
N Missing	1
Systolic Blood Pressure (mmHg)	
Median (Q1, Q3)	128 (124, 150)
Mean (SD)	130 (19)
Min, Max	100, 152
Diastolic Blood Pressure (mmHg)	
Median (Q1, Q3)	77 (65, 84)
Mean (SD)	75 (11)
Min, Max	60, 87

Table 8 presents a summary of ECOG performance status grade at time of screening for all 6 registered participants.

Table 8: Summary of ECOG Performance Status

	N = 6
ECOG performance status grade	
0	2 (33%)
1	2 (33%)
2	0 (0%)
3	2 (33%)
4	0 (0%)

Table 9 presents a summary of the virology assessments at time of screening for all 6 registered participants.

Table 9: Summary of Virology Assessments

	N = 6
Timing of assessment	
Transplant preparation	6 (100%)
Screening	0 (0%)
HIV	
Positive	0 (0%)
Negative	6 (100%)
Not done	0 (0%)
Hepatitis B	
Positive	0 (0%)
Negative	6 (100%)
Not done	0 (0%)
Hepatitis C	
Positive	0 (0%)
Negative	6 (100%)
Not done	0 (0%)

Table 10 summarises the blood chemistry assessment results at time of screening for all 6 registered participants.

Table 10: Summary of Blood Chemistry Assessment

	N = 6
Albumin (g/L)	
Median (Q1, Q3)	28 (20, 30)
Mean (SD)	26 (8)
Min, Max	14, 37
Alkaline Phosphatase (U/L)	
Median (Q1, Q3)	120 (90, 206)
Mean (SD)	149 (95)
Min, Max	50, 311
Alanine Aminotransferae (U/L)	
Median (Q1, Q3)	25 (14, 31)
Mean (SD)	25 (14)
Min, Max	10, 45
Missing	1
Aspartate Transminase (U/L)	
Median (Q1, Q3)	20 (17, 36)
Mean (SD)	24 (10)
Min, Max	17, 36
Missing	3
Bicarbonate (mmol/L)	
Median (Q1, Q3)	18 (16, 29)
Mean (SD)	21 (7)
Min, Max	16, 29
Missing	3
Bilirubin (µ/L)	
Median (Q1, Q3)	11 (8, 14)
Mean (SD)	11 (6)
Min, Max	4, 21
Calcium (mmol)	
Median (Q1, Q3)	2.27 (2.03, 2.40)
Mean (SD)	2.21 (0.22)
Min, Max	1.87, 2.43
Creatinine (µ/L)	
Median (Q1, Q3)	67 (60, 76)
Mean (SD)	68 (14)
Min, Max	50, 90
Potassium (mmol/L)	
Median (Q1, Q3)	4.25 (3.60, 4.70)
Mean (SD)	4.27 (0.68)
Min, Max	3.50, 5.30
Lactate Dehydrogenase (U/L)	
Median (Q1, Q3)	271 (256, 286)
Mean (SD)	271 (21)
Min, Max	256, 286
Missing	4

Table 10: Summary of Blood Chemistry Assessment *(continued)*

	N = 6
Magnesium (mmol/L)	
Median (Q1, Q3)	0.74 (0.60, 0.88)
Mean (SD)	0.74 (0.14)
Min, Max	0.58, 0.91
Phosphate (mg/dL)	
Median (Q1, Q3)	0.99 (0.85, 1.10)
Mean (SD)	1.04 (0.31)
Min, Max	0.70, 1.60
Total Protein (g/L)	
Median (Q1, Q3)	56 (42, 57)
Mean (SD)	52 (8)
Min, Max	42, 57
Missing	3
Sodium (mmol/L)	
Median (Q1, Q3)	139 (135, 141)
Mean (SD)	138 (4)
Min, Max	132, 142
Urea (mmol/L)	
Median (Q1, Q3)	8.0 (5.8, 8.3)
Mean (SD)	8.7 (6.7)
Min, Max	1.8, 19.8
Missing	1

Table 11 summarises the haematology assessment results at time of screening for all 6 registered participants.

Table 11: Summary of Haematology Assesments

	N = 6
Haemoglobin (g/L)	
Median (Q1, Q3)	92 (85, 110)
Mean (SD)	94 (16)
Min, Max	73, 114
Lymphocytes (10^9/L)	
Median (Q1, Q3)	0.40 (0.20, 0.50)
Mean (SD)	0.60 (0.70)
Min, Max	0.10, 2.00
Neutrophils (10^9/L)	
Median (Q1, Q3)	4.75 (3.00, 8.60)
Mean (SD)	5.50 (2.97)
Min, Max	2.30, 9.60
Platelets (10^9/L)	
Median (Q1, Q3)	131 (71, 174)
Mean (SD)	117 (72)
Min, Max	8, 190
White Blood Cells (10^9/L)	
Median (Q1, Q3)	5.55 (3.60, 11.00)
Mean (SD)	6.68 (3.61)
Min, Max	3.10, 11.30

At the time of screening, aGvHD scoring was performed in all 6 registered participants. Table 12 presents a summary of aGvHD scoring performance at time of screening.

The Overall Clinical Grade is based upon the most severe target organ involvement, and is defined as:

- Grade 0: No stage 1-4 of any organ
- Grade I: Stage 1-2 skin without liver, upper GI or lower GI involvement
- Grade II: Stage 3 rash and/or stage 1 liver and/or stage 1 upper GI and/or stage 1 lower GI
- Grade III: Stage 2-3 liver and/or stage 2-3 lower GI, with stage 0-3 skin and/or stage 0-1 upper GI
- Grade IV: Stage 4 skin, liver or lower GI involvement, with stage 0-1 upper GI

Table 12: Summary of aGvHD scoring performance

	N = 6
Skin (active erythema only)	
Stage 0	4 (67%)
Stage 1	1 (17%)
Stage 2	1 (17%)
Stage 3	0 (0%)
Stage 4	0 (0%)
Liver (bilirubin)	
Stage 0	6 (100%)
Stage 1	0 (0%)
Stage 2	0 (0%)
Stage 3	0 (0%)
Stage 4	0 (0%)
Upper GI	
Stage 0	5 (83%)
Stage 1	1 (17%)
Lower GI (stool output/day)	
Stage 0	1 (17%)
Stage 1	1 (17%)
Stage 2	2 (33%)
Stage 3	1 (17%)
Stage 4	1 (17%)
Acute GvHD Overall Clinical Grade	
Grade 0	0 (0%)
Grade I	0 (0%)
Grade II	2 (33%)
Grade III	3 (50%)
Grade IV	1 (17%)

At the time of screening, cGvHD scoring was performed in all 6 registered participants. Tables 13-22 summarises the cGvHD assessment evaluation at time of screening.

Table 13: Summary of cGvHD scoring - performance score

	N = 6
Performance score	
0	3 (50%)
1	0 (0%)
2	0 (0%)
3	3 (50%)

Table 14: Summary of cGvHD SKIN scoring

	N = 6
Score (%BSA)	
0: No BSA involved	5 (83%)
1: 1 - 18% BSA	1 (17%)
2: 19 - 50% BSA	0 (0%)
3: > 50% BSA	0 (0%)
Skin features score	
0: No sclerotic features	6 (100%)

Table 15: Summary of cGvHD Other Skin Features

	N = 6
Skin GvHD features scored by BSA	
Maculopapular rash / erythema1	1 (17%)
None	5 (83%)
Skin features score	
None	6 (100%)
Other skin GvHD features (NOT scored by BSA)	
None	6 (100%)

Table 16: Summary of cGvHD Mouth scoring

	N = 6
Mouth Score	
0	6 (100%)
1	0 (0%)
2	0 (0%)
3	0 (0%)
Are lichen plannus-like features present?	
No	6 (100%)
Yes	0 (0%)

Table 17: Summary of cGvHD Eyes scoring

	N = 6
Eyes Score	
0	6 (100%)
1	0 (0%)
2	0 (0%)
3	0 (0%)

Table 18: Summary of cGvHD GI Tract scoring

	N = 6
GI Tract Score	
0	3 (50%)
1	0 (0%)
2	0 (0%)
3	3 (50%)
GI Tract Symptoms	
Diarrhoea	3 (100%)

Table 19: Summary of cGvHD Liver scoring

	N = 6
Liver Score	
0	6 (100%)
1	0 (0%)
2	0 (0%)
3	0 (0%)

Table 20: Summary of Lungs Symptom scoring

	N = 6
Lungs Symptom Score	
0	6 (100%)
1	0 (0%)
2	0 (0%)
3	0 (0%)
Lung Score (% FEV1)	
0	1 (17%)
1	0 (0%)
2	0 (0%)
3	0 (0%)
Not performed	5 (83%)

Table 21: Summary of Joints and Fascia scoring

	N = 6
Joints and Fascia Score	
0	6 (100%)
1	0 (0%)
2	0 (0%)
3	0 (0%)

Joints and Fascia scores using Photographic Range of Motion (P-ROM) was not performed for 5 participants. 1 participant reported a score of 7 (Normal) for the shoulder, elbow and wrist/finger scores, and an ankle score of 4 (Normal).

Table 22: Summary of Genital Tract Scoring

	Registered N = 6
Genital Tract Score	
0	1 (17%)
1	0 (0%)
2	0 (0%)
3	0 (0%)
Not examined	5 (83%)
Is the patient sexually active?	
No	1 (100%)
Yes	0 (0%)
Missing	5

0 participants reported any clinical features or complications related to chronic GvHD, and hence scores relating to these were not specified.

All 6 participants reported No chronic GvHD at screening.

Outcome Measures

Due to the trial closing to recruitment early the secondary outcomes of recruitment time, defined to be the time taken to complete recruitment and biomarker assay accuracy could not be determined and as such are not presented here.

Table 23: Trial Outcome Measures

Endpoints	
	Primary Endpoint
Grade 3 or higher AESI (N (%))	0/6 (0%)
Number of Grade 3 AEs	11 (4 patients)
	Secondary Endpoints
Overall GvHD Response Rate* (N (%))	3/5 (60%)
Recruitment of High & Intermediate Risk Participants (N (%))**	9/15 (60%)
Laboratory Turn Around Time (days) (Median IQR)**	1 day (1 -2 days)

* One patient was not evaluable for this outcome

** Outcome presented for all screened participants who had biomarker assay completed n =15 (6 registered, 9 not registered)

Adverse Events

Table 24: All Reported Serious Adverse Event Line Listing

Time from Start of Trial Treatment to Onset (Weeks)	Category	Event	Reason for SAE Reporting	Grade	Length of Event (Weeks)	Related	Outcome	Sequel	Other Events	Other Event Grades
1.4	Fatal/life-threatening SUSAR	Life-threatening; Hospitalisation	Colonic perforation	4	2.4	Possibly related	Resolved - with sequelae	Stoma (colostomy)		
8.6	Unrelated SAE	Life-threatening; Hospitalisation	Gastric hemorrhage	4		Unlikely to be related	Unresolved			
8.6	Unrelated SAE	Death; Life-threatening	Other - GI GvHD	5	6.4	Unrelated	Death			
24.1	Unrelated SAE	Hospitalisation	Lung infection	3		Unlikely to be related	Resolved - with sequelae	Reduced performance status		
1.4	Unrelated SAE	Death	Colonic perforation	5	0	Unlikely to be related	Death		Lung infection	4

Table 25 summarises SAE details, including relatedness and fatality.

Table 25: Serious Adverse Event details, capturing relatedness and fatality

Category	Toxicity	Affected	Exposed	Occurrences	Fatal	Related	Related and Fatal	Percentage Affected (%)
Gastrointestinal disorders	Colonic perforation	2	6	2	1	1	0	33.33
Gastrointestinal disorders	GI GvHD	1	6	1	1	0	0	16.67
Gastrointestinal disorders	Gastric hemorrhage	1	6	1	0	0	0	16.67
Infections and infestations	Lung infection	1	6	1	0	0	0	16.67

Table 26: Summary of all adverse events.

Category	**Toxicity**	**Grade**	**Overall number of Events (Participants Affected)**
Blood and lymphatic system disorders		1	1 (1)
	Anemia	3	1 (1)
Ear and labyrinth disorders	Hearing impaired	1	1 (1)
Gastrointestinal disorders		4	1 (1)
	Colonic perforation	5	1 (1)
	Diarrhoea	3	1 (1)
	GI GvHD	5	1 (1)
	Gastric hemorrhage	4	1 (1)
	Upper gastrointestinal hemorrhage	3	1 (1)
General disorders and administration site conditions	Edema limbs	2	1 (1)
Infections and infestations		3	1 (1)
	Lung infection	4	1 (1)
	mycobacterium neoaurum	2	1 (1)
Investigations	Creatinine increased	2	1 (1)
	Platelet count decreased	4	1 (1)
Renal and urinary disorders	Acute kidney injury	3	1 (1)

Table 26 summarises the adverse events experienced by at least 5% of participants on the trial by CTCAE category and toxicity.

Table 26: Adverse Events experienced by at least 5 percent of participants on the trial by CTCAE category and toxicity. Use for Eudract submission.

Category	**Toxicity**	**Affected**	**Exposed**	**Occurences**	**Percentage Affected**
Blood and lymphatic system disorders	Anemia	2	6	2	33.33
Ear and labyrinth disorders	Hearing impaired	1	6	1	16.67
	Colonic perforation	2	6	2	33.33
	Diarrhoea	1	6	1	16.67
	GI GvHD	1	6	1	16.67
	Gastric hemorrhage	1	6	1	16.67
Gastrointestinal disorders	Upper gastrointestinal hemorrhage	1	6	1	16.67
General disorders and administration site conditions	Edema limbs	1	6	1	16.67
	Lung infection	2	6	2	33.33
Infections and infestations	mycobacterium neoaurum	1	6	1	16.67
	Creatinine increased	1	6	1	16.67
Investigations	Platelet count decreased	1	6	1	16.67
Renal and urinary disorders	Acute kidney injury	1	6	1	16.67

Table 27 presents a line listing of all adverse events experienced.

Table 27: Adverse Event Line Listing

Time from Start of Trial Treatment to Onset (Weeks)	Category	Event	Grade	Ongoing?	Length of Event (Weeks)	Relatedness	Pre-existing Condition?	SAE?	AESI?	Has the Patient Died?	Outcome
14.1	Blood and lymphatic system disorders	Anemia	1	No	3	Unrelated	No	No	No	Yes	Resolved no sequelae
24.1	Infections and infestations	Lung infection	3	No	40.3	Unrelated	No	No	No	Yes	Not known
1.0	Gastrointestinal disorders	Colonic perforation	4	No	2.9	Possibly related	No	Yes	No	No	Resolved with sequelae
0.9	Infections and infestations	Lung infection	4	No	0.6	Probably related	No	No	No	Yes	Not known
1.4	Gastrointestinal disorders	Colonic perforation	5	Yes		Unlikely to be related	No	Yes	No	Yes	Unresolved
5.0	Ear and labyrinth disorders	Hearing impaired	1	No	4.1	Unrelated	No	No	No	No	Resolved no sequelae
2.3	Gastrointestinal disorders	Diarrhoea	3	No	0.4	Unlikely to be related	No	No	No	Yes	Resolved no sequelae
3.1	Gastrointestinal disorders	Upper gastrointestinal hemorrhage	3	Yes		Unlikely to be related	No	No	No	Yes	Unresolved
4.0	General disorders and administration site conditions	Edema limbs	2	Yes		Possibly related	No	No	No	Yes	Unresolved
4.6	Renal and urinary disorders	Acute kidney injury	3	No	2	Possibly related	No	No	No	Yes	Resolved no sequelae
6.0	Infections and infestations	Other - mycobacterium neoaurum	2	No	5.3	Unlikely to be related	No	No	No	Yes	Resolved no sequelae
6.9	Investigations	Platelet count decreased	4	Yes		Unrelated	No	No	No	Yes	Unresolved
7.6	Blood and lymphatic system disorders	Anemia	3	No	3.7	Unlikely to be related	No	No	No	Yes	Resolved no sequelae

Table 27: Adverse Event Line Listing *(continued)*

Time from Start of Trial Treatment to Onset (Weeks)	Category	Event	Grade	Ongoing?	Length of Event (Weeks)	Relatedness	Pre-existing Condition?	SAE?	AESI?	Has the Patient Died?	Outcome
8.6	Gastrointestinal disorders	Gastric hemorrhage	4	Yes		Unlikely to be related	No	Yes	No	Yes	Unresolved
8.6	Gastrointestinal disorders	Other - GI GvHD	5	No	6.4	Unrelated	No	Yes	No	Yes	Resolved with sequelae
10.6	Investigations	Creatinine increased	2	Yes		Unrelated	No	No	No	Yes	Unresolved

* The Grade 3 Lung Infection experienced was an SAE which was deemed unrelated to Lenzilumab and Resolved - with sequelae. Further information can be found in Table 24.
† The Grade 5 GI GvHD experienced was an SAE which had an outcome of Death. Further information can be found in Table 24.
‡ The Grade 5 Colonic Perforation experienced was an SAE which had an outcome of Death. Further information can be found in Table 24.